The FDA held public hearings just last week to discuss establishing guidelines for pharmaceutical marketers operating in the new world of social media. Already some are complaining that the process is taking too long.
“Does the FDA get it?” If it did, “they wouldn’t be having this meeting now, many, many months after it was already apparent how quickly Web communications is changing,” Mark Senak, author of the blog Eye on FDA and a senior vice-president at Fleishman-Hillard told BusinessWeek.
John Bell, President of the Board of Word of Mouth Marketing Association and Managing Director, Ogilvy Public Relations Worldwide agreed that things will take a while. “We’re spending time today in initial discussions that is as much about how the process should unfold as it is what should be the precise guidelines,” he told PRNewser last week.
- Kate Spade's CMO: ‘The Customer Has a Voice and So Do We'
- Some Writers Not So Hot on Amtrak's 'Writers' Residencies' Campaign
- One Way to Engage: Tell Followers Things About Themselves
- Metropolitan Museum's Chief Digital Officer Shares His Artful Perspective on Social Media